To address the needs and complexity of our growing enterprise, Sidney Kimmel Cancer Center at Jefferson (SKCC) has announced that Andrew Chapman, DO, FACP, will serve in an interim role as the new enterprise-wide Chief of Cancer Services, a role that will also include Aria-Jefferson Health and Abington-Jefferson Health.
Dr. Chapman brings significant expertise from his years of leadership within Thomas Jefferson University and Jefferson’s Department of Medical Oncology, where he leads the geriatric oncology program and serves as Vice Chair of Operations.
In this position, Dr. Chapman is charged with system-wide leadership in sustaining preeminence in the SKCC tripartite mission of patient care, education, and research in all disciplines touching cancer patients across Jefferson Health. These include but are not limited to surgical oncology, radiation oncology, medical oncology, and nursing oncology. Among other duties, Dr. Chapman will lead and guide our efforts to provide an exceptional patient experience, maximizing Jefferson Health-wide consistency, standardizing and promoting interdisciplinary approaches, facilitating access to the most advanced cancer care and clinical trials, and strategic planning for cancer care across the enterprise. Over the next six to 12 months, the Chief of Cancer Services role will be formalized with Dr. Chapman’s input and a permanent Chief will be appointed.
This new role will complement the current leadership role of Matthew Carabasi, MD, who continues his Jefferson Health responsibilities as the Senior Director of Strategic Oncology Partnerships. Dr. Carabasi is Professor and Vice Chair of Outreach for the Jefferson Department of Medical Oncology as well as Director of the Medical Oncology Specialty Network.
Drs. Carabasi and Chapman will partner to ensure access to the most advanced care and provide strategic planning for growth in the Jefferson Health-consolidated cancer service line.
“There is a reason that the Sidney Kimmel Cancer Center at Jefferson continues to be one of the top-ranked cancer centers in the United States, year after year — our passion for discovery, capacity for driving exceptional interdisciplinary teams, and commitment to providing the most advanced cancer care to our patients are differentiators recognized in Philadelphia and beyond,” said Karen Knudsen, PhD, Director of SKCC . “We are thankful to Drs. Chapman and Carabasi for serving in these leadership roles, each critical to achieving the SKCC goal: until every cancer is cured.”